MedTrace Logo

Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function

NCT07682818 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-07-06

No results posted yet for this study

Summary

This clinical research trial is testing the investigational medicinal product (IMP) petrelintide that is being developed for body weight reduction in people living with obesity or overweight who have comorbidities.

The aim of this clinical research trial is to investigate whether the pharmacokinetics (PK) of petrelintide will be different in people with hepatic impairment (HI) compared to people with normal hepatic function.

Conditions

  • Impaired Hepatic Function

Interventions

DRUG

Petrelintide

Petrelintide will be administered as a single SC injection.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trial Information Desk · Zealand Pharma A/S

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-18
Primary Completion
2027-04-12
Completion
2027-04-12

Countries

  • Poland
  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07682818 on ClinicalTrials.gov